MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy

Abstract Gastrointestinal cancers account for a substantial share of global cancer burden. We assessed the significance of MTAP loss across 1545 resected tumors (cholangiocarcinoma, esophageal and gastric adenocarcinoma, pancreatic ductal adenocarcinoma). MTAP protein was evaluated by immunohistoche...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Su Ir Lyu, Karl Knipper, Caroline Fretter, Eleni Tzitzili, Adrian Georg Simon, Hakan Alakus, Aylin Pamuk, Christiane J. Bruns, Thomas Schmidt, Felix C. Popp, Alexander Quaas
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2026-05-01
Serie:	Scientific Reports
Soggetti:	MTAP-loss Esophageal cancer Gastric cancer Pancreatic cancer PRMT5-inhibitor
Accesso online:	https://doi.org/10.1038/s41598-026-51370-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!